Furthermore, we show that SMARCA4 upregulation is associated with a poor prognosis in published datasets for breast and ovarian cancer, lung adenocarcinoma, liposarcoma, and uveal melanoma and in the SKCM, LIHC, BLCA, and KIRC TCGA cohorts, indicating that high expression of SMARCA4 can be used as a prognosis marker for these types of tumors. This evidence concerns the gene SMARCA4 and bladder transitional cell carcinoma.